Christopher Broder

Summary

Affiliation: Uniformed Services University of the Health Sciences
Country: USA

Publications

  1. pmc Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10690. 2010
  2. ncbi request reprint Immunization strategies against henipaviruses
    Christopher C Broder
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    Curr Top Microbiol Immunol 359:197-223. 2012
  3. doi request reprint Henipavirus outbreaks to antivirals: the current status of potential therapeutics
    Christopher C Broder
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, United States
    Curr Opin Virol 2:176-87. 2012
  4. pmc Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein
    Katharine N Bossart
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    Virol J 2:57. 2005
  5. pmc The YPLGVG sequence of the Nipah virus matrix protein is required for budding
    Jared R Patch
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    Virol J 5:137. 2008
  6. pmc Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein
    Jared R Patch
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    Virol J 4:1. 2007
  7. pmc Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infection
    Jorge C G Blanco
    Virion Systems Inc, 9610 Medical Center Drive, Suite 100, Rockville, Maryland 20850, USA
    Virol J 6:57. 2009
  8. pmc Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding
    Kimberly A Bishop
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    J Virol 82:11398-409. 2008
  9. pmc A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system
    Dimple Khetawat
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    Virol J 7:312. 2010
  10. pmc Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus
    Katharine N Bossart
    Department of Microbiology and Immunology, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814 4799, USA
    J Virol 79:6690-702. 2005

Research Grants

  1. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 1999
  2. HIV-1 Fusion Coreceptors
    Christopher Broder; Fiscal Year: 2007
  3. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2006
  4. HIV-1 Fusion Coreceptors
    Christopher Broder; Fiscal Year: 2006
  5. Nipah virus and Hendra virus Peptide Therapeutics
    Christopher Broder; Fiscal Year: 2006
  6. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2009
  7. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 2001
  8. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 2000
  9. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2007
  10. Nipah Virus and Hendra Virus Subunit Vaccines
    Christopher Broder; Fiscal Year: 2006

Collaborators

Detail Information

Publications42

  1. pmc Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10690. 2010
    ....
  2. ncbi request reprint Immunization strategies against henipaviruses
    Christopher C Broder
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    Curr Top Microbiol Immunol 359:197-223. 2012
    ..Several henipavirus challenge models have been used and recent successes in both active and passive immunization strategies against henipaviruses have been reported which have all targeted the viral envelope glycoproteins...
  3. doi request reprint Henipavirus outbreaks to antivirals: the current status of potential therapeutics
    Christopher C Broder
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, United States
    Curr Opin Virol 2:176-87. 2012
    ..Here, recent findings on the few most advanced henipavirus countermeasures are summarized and discussed...
  4. pmc Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein
    Katharine N Bossart
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    Virol J 2:57. 2005
    ..Here, we have evaluated these peptides as well as the corresponding scrambled peptide controls in Nipah virus and Hendra virus-mediated membrane fusion and against infection by live virus in vitro...
  5. pmc The YPLGVG sequence of the Nipah virus matrix protein is required for budding
    Jared R Patch
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    Virol J 5:137. 2008
    ..Here, we have used this system to further explore the budding process by analyzing elements within the M protein that are critical for particle release...
  6. pmc Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein
    Jared R Patch
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    Virol J 4:1. 2007
    ..Here, we have established recombinant expression systems to study NiV particle assembly and budding through the formation of virus-like particles (VLPs)...
  7. pmc Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infection
    Jorge C G Blanco
    Virion Systems Inc, 9610 Medical Center Drive, Suite 100, Rockville, Maryland 20850, USA
    Virol J 6:57. 2009
    ....
  8. pmc Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding
    Kimberly A Bishop
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    J Virol 82:11398-409. 2008
    ..Together, these data suggest the stalk domain of G plays an important role in the conformational stability and receptor binding-triggered changes leading to productive fusion, such as the dissociation of G and F...
  9. pmc A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system
    Dimple Khetawat
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    Virol J 7:312. 2010
    ....
  10. pmc Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus
    Katharine N Bossart
    Department of Microbiology and Immunology, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814 4799, USA
    J Virol 79:6690-702. 2005
    ..This HeV sG glycoprotein will be exceedingly useful for structural studies, receptor identification strategies, and vaccine development goals for these important emerging viral agents...
  11. pmc Identification of Hendra virus G glycoprotein residues that are critical for receptor binding
    Kimberly A Bishop
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    J Virol 81:5893-901. 2007
    ....
  12. pmc Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization
    Peng Fei Zhang
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 104:10193-8. 2007
    ..Neutralization was IgG-mediated and HIV-1-specific. These results demonstrate that induction of truly broad spectrum neutralizing antibodies is an achievable goal in HIV-1 vaccine development...
  13. pmc Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells
    Gerald V Quinnan
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    J Virol 79:3358-69. 2005
    ..Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain...
  14. pmc Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus
    Matthew I Bonaparte
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 102:10652-7. 2005
    ..Together, these data indicate that EFNB2 serves as a functional receptor for both HeV and NiV. The highly conserved nature of EFNB2 in humans and animals is consistent with the broad tropism exhibited by these emerging zoonotic viruses...
  15. ncbi request reprint Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry
    Ingrid Markovic
    Center for Drug Evaluation and Research, Food and Drug Adminiatration, Bethesda, MD, USA
    Blood 103:1586-94. 2004
    ....
  16. pmc Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine
    Bruce A Mungall
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    J Virol 80:12293-302. 2006
    ..These results indicate that the cat provides a consistent model for acute NiV infection and associated pathogenesis and an effective subunit vaccine strategy appears achievable...
  17. pmc The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages
    Tzanko S Stantchev
    Department of Microbiology and Immunology, F Edward Hebert School of Medicine, Uniformed Services University Bethesda, 4301 Jones Bridge Road, MD 20814, USA
    Virus Res 123:178-89. 2007
    ..These findings suggest that other exploitable targets, or steps, of the HIV-1 infection process may exist and could serve as additional opportunities for the development of new therapeutics...
  18. pmc Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins
    Katharine N Bossart
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
    J Virol 76:11186-98. 2002
    ..However, no heterotypic activity was observed with envelope glycoproteins of the morbilliviruses Measles virus and Canine distemper virus...
  19. pmc Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery
    Yee Peng Chan
    Uniformed Services, University of the Health Sciences, Bethesda, MD, USA
    Methods Mol Biol 525:31-58, xiii. 2009
    ....
  20. ncbi request reprint Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses
    Zhongyu Zhu
    Protein Interactions Group, CCRNP, BRP, SAIC Frederick, Inc, NCI Frederick, NIH Bldg 469, Rm 139, PO Box B, MD 21702 1201, USA
    Expert Rev Anti Infect Ther 4:57-66. 2006
    ....
  21. pmc Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes
    Maxime Moulard
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:6913-8. 2002
    ....
  22. doi request reprint A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats
    Jennifer A McEachern
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    Vaccine 26:3842-52. 2008
    ..The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses...
  23. pmc Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3
    Kai Xu
    Structural Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 105:9953-8. 2008
    ..The structures further suggest that the NiV-G/ephrin interactions can be effectively targeted to disrupt viral entry and provide the foundation for structure-based antiviral drug design...
  24. pmc Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody
    Mei Yun Zhang
    Human Immunovirology Group, Laboratory of Experimental and Computational Biology, Center for Cancer Research, National Cancer Institute Frederick, NIH, Frederick, Maryland 21702 1201, USA
    J Virol 78:9233-42. 2004
    ....
  25. ncbi request reprint Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors
    Katharine N Bossart
    Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, WI, USA
    Methods Mol Biol 269:309-32. 2004
    ..This chapter will detail the methods of the vaccinia virus-based reporter-gene fusion assay and how it may be used to characterize the fusion mediated by the BSL-4-classified Hendra and Nipah viruses...
  26. ncbi request reprint Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity
    Xiaodong Xiao
    Laboratory of Experimental and Computational Biology, National Cancer Institute Frederick, NIH, Bldg 469, Rm 246, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    Vaccine 21:4275-84. 2003
    ..These findings suggest that stable purified Env-CD4-CCR5(CXCR4) complexes can be produced in relatively large amount sufficient for their further characterization that may help in the development of novel vaccines candidates...
  27. ncbi request reprint Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library
    Mei Yun Zhang
    Laboratory of Experimental and Computational Biology, CCR, NCI Frederick, NIH, Bldg 469, Rm 246, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    J Immunol Methods 283:17-25. 2003
    ..The methodology and the results may have implications for development of HIV vaccines and inhibitors, as well as for identification of antibodies to conserved epitopes on rapidly mutating viruses and cells...
  28. pmc Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins
    Diana I Albu
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208, USA
    J Virol 77:5589-97. 2003
    ....
  29. ncbi request reprint Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry
    Angelo Gallina
    Department of Pathology and Microbiology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 277:50579-88. 2002
    ..Conformational changes resulting from the opening of gp120-disulfide loops may drive the processes of virus-cell and cell-cell fusion. The biochemical events described identify new potential targets for anti-HIV agents...
  30. pmc Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens
    Mei Yun Zhang
    CCRNP, CCR, NCI Frederick, NIH, Bldg 469, Rm 131, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    J Virol 82:6869-79. 2008
    ..Its novel conserved conformational epitope on gp41 could be helpful in the design of vaccine immunogens and as a target for therapeutics...
  31. doi request reprint Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody
    Zhongyu Zhu
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, Center for Cancer Research, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    J Infect Dis 197:846-53. 2008
    ..These results suggest that m102.4 has potential as a therapeutic agent for the treatment of diseases caused by henipaviruses. It could be also used for prophylaxis and diagnosis, and as a research reagent...
  32. ncbi request reprint Functional studies of host-specific ephrin-B ligands as Henipavirus receptors
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia
    Virology 372:357-71. 2008
    ....
  33. ncbi request reprint Hendra and Nipah viruses: pathogenesis and therapeutics
    Bryan T Eaton
    Australian Animal Health Laboratory, CSIRO, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    Curr Mol Med 5:805-16. 2005
    ....
  34. ncbi request reprint Developments towards effective treatments for Nipah and Hendra virus infection
    Katharine N Bossart
    Australian Animal Health Laboratory, CSIRO Livestock Industries, Geelong, Victoria 3220, Australia
    Expert Rev Anti Infect Ther 4:43-55. 2006
    ....
  35. pmc Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies
    Vidita Choudhry
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD 21702, USA
    Virology 363:79-90. 2007
    ....
  36. pmc Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies
    Zhongyu Zhu
    CCRNP, CCR, NCI Frederick, NIH, Frederick, MD 21702, USA
    J Virol 80:891-9. 2006
    ....
  37. pmc Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning
    Mei Yun Zhang
    Protein Interactions Group, CCRNP, CCR, NCI Frederick, NIH, Frederick, Maryland 21702, USA
    J Immunol Methods 317:21-30. 2006
    ..These results may have implications for the selection of novel gp41-specific bcnAbs and other antibodies, and for the development of HIV-1 inhibitors and vaccine immunogens...
  38. ncbi request reprint Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens
    Yen Hung Chow
    Laboratory of Experimental and Computational Biology, National Cancer Institute Frederick, NIH, Miller Drive, Frederick, Maryland 21702 1201, USA
    Biochemistry 41:7176-82. 2002
    ..Thus, tethered Envs with long linkers may not only be important as HIV-1 inhibitors but also for elucidation of viral entry mechanisms and development of novel vaccine immunogens...
  39. ncbi request reprint Hendra and Nipah viruses: different and dangerous
    Bryan T Eaton
    Australian Animal Health Laboratory, Commonwealth Scientific and Industrial Research Organization, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    Nat Rev Microbiol 4:23-35. 2006
    ....
  40. ncbi request reprint Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses
    Andrew J Sloane
    HIV Protein Interactions Laboratory, Centre for Virus Research, Westmead, NSW, Australia
    Immunol Cell Biol 83:129-43. 2005
    ..This separation of structure and function has implications for understanding HIV-1 entry and SDF-1alpha responses and may indicate therapeutic possibilities...
  41. ncbi request reprint Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat
    Bruce A Mungall
    Commonwealth Scientific and Industrial Research Organisation, Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria, Australia
    J Infect Dis 196:812-6. 2007
    ....
  42. pmc Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection
    Derek Dube
    Department of Microbiology, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22908 0734, USA
    J Virol 82:7238-42. 2008
    ..Furthermore, with 293F cells the acquisition of EboV RBD binding paralleled cell spreading and did not require new mRNA or protein synthesis...

Research Grants16

  1. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 1999
    ....
  2. HIV-1 Fusion Coreceptors
    Christopher Broder; Fiscal Year: 2007
    ..abstract_text> ..
  3. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2006
    ....
  4. HIV-1 Fusion Coreceptors
    Christopher Broder; Fiscal Year: 2006
    ..abstract_text> ..
  5. Nipah virus and Hendra virus Peptide Therapeutics
    Christopher Broder; Fiscal Year: 2006
    ..We will establish the required experimental conditions and parameters and test this hypothesis in a NiV infection model using the cat. ..
  6. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2009
    ....
  7. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 2001
    ....
  8. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 2000
    ....
  9. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2007
    ....
  10. Nipah Virus and Hendra Virus Subunit Vaccines
    Christopher Broder; Fiscal Year: 2006
    ..We will evaluate monoclonal and polyclonal antibodies in both reporter-gene membrane fusion assays and in virus-neutralization assays. ..
  11. HIV-1 Fusion Coreceptors
    Christopher Broder; Fiscal Year: 2005
    ..abstract_text> ..
  12. HIV-1 FUSION COFACTORS
    Christopher Broder; Fiscal Year: 2002
    ....
  13. Nipah Virus and Hendra Virus Entry and Virion Assembly
    Christopher Broder; Fiscal Year: 2010
    ....